Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02429934 · ClinicalTrials.gov registry record · Phase 1
Abatacept for SLE Arthritis (IM101-330)
A Phase 1 study, sponsored by University of California, Los Angeles.
- Terminated
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT02429934 is a Phase 1 study that was terminated before completion, run by University of California, Los Angeles. The registered enrollment target is 28 participants.
The verdict
NCT02429934, a Phase 1 study, was terminated before completion, sponsored by University of California, Los Angeles.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
This research trial is for patients who have been diagnosed with systemic lupus erythematosus (SLE) with swollen, tender joints (which is called inflammatory polyarthritis) because of the SLE. The purpose of this clinical research study is to evaluate the safety and effectiveness of treatment with abatacept (Abatacept) 125mg injected subcutaneously (under the skin) weekly for 16 weeks versus placebo injections(a substance with no active ingredients and therefore may have no treatment benefit) in subjects with SLE and inflammatory polyarthritis. The effectiveness will be assessed primarily by the number of swollen, tender joints (called a joint count) at each of study visits. Study Medication Abatacept is approved in the U.S. for treating rheumatoid arthritis by prescription and has not been approved by the U.S. Food and Drug Administration for treating SLE yet. In this study, subjects will receive treatment with either abatacept or placebo once a week for 16 weeks (a total of 16 injections).
Interventions
- DRUG Placebo
- BIOLOGICAL abatacept also known as Orencia also known as CTLA4-Ig
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2015-10 |
| Est. Completion | 2019-09-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02429934
The ClinicalTrials.gov registry entry for NCT02429934 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Los Angeles, which has 897 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02429934 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02429934 about?
NCT02429934 is a clinical study titled "Abatacept for SLE Arthritis (IM101-330)". This research trial is for patients who have been diagnosed with systemic lupus erythematosus (SLE) with swollen, tender joints (which is called inflammatory polyarthritis) because of the SLE. The purpose of this clinical research study is to evaluate the safety and effectiveness of treatment with ...
What is the current status of trial NCT02429934?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2015-10. Estimated completion is 2019-09-01.
What interventions are being tested in trial NCT02429934?
The interventions under investigation include: Placebo (DRUG), abatacept also known as Orencia also known as CTLA4-Ig (BIOLOGICAL).
Who is sponsoring clinical trial NCT02429934?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.